Evolution-guided protein design of IscB for persistent epigenome editing in vivo

Soumya Kannan^#^{1

2

3

4

5

6}, Han Altae-Tran^#^{1

2

3

4

5

6}, Shiyou Zhu^#^{1

2

3

4

5

6}, Peiyu Xu^{1

2

3

4

5

6}, Daniel Strebinger^{1

2

3

4

5

6}, Rachel Oshiro^{1

2

3

4

5

6}, Guilhem Faure^{1

2

3

4

5

6}, Lukas Moeller^{1

2

3

4

5

6}, Julie Pham^{1

2

3

4

5

6}, Kepler S Mears^{1

2

3

4

5

6}, Heyuan M Ni⁵, Rhiannon K Macrae^{1

2

3

4

5

6}, Feng Zhang^{7

8

9

10

11

12}

Affiliations

¹ Howard Hughes Medical Institute, Cambridge, MA, USA.
² Broad Institute of MIT and Harvard, Cambridge, MA, USA.
³ McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
⁴ Department of Brain and Cognitive Science, Massachusetts Institute of Technology, Cambridge, MA, USA.
⁵ Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
⁶ Yang Tan Collective, Cambridge, MA, USA.
⁷ Howard Hughes Medical Institute, Cambridge, MA, USA. zhang@broadinstitute.org.
⁸ Broad Institute of MIT and Harvard, Cambridge, MA, USA. zhang@broadinstitute.org.
⁹ McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, MA, USA. zhang@broadinstitute.org.
¹⁰ Department of Brain and Cognitive Science, Massachusetts Institute of Technology, Cambridge, MA, USA. zhang@broadinstitute.org.
¹¹ Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. zhang@broadinstitute.org.
¹² Yang Tan Collective, Cambridge, MA, USA. zhang@broadinstitute.org.

^# Contributed equally.

PMID: 40335752
DOI: 10.1038/s41587-025-02655-3

Evolution-guided protein design of IscB for persistent epigenome editing in vivo

Soumya Kannan et al. Nat Biotechnol. 2025.

. 2025 May 7.

doi: 10.1038/s41587-025-02655-3. Online ahead of print.

Authors

Affiliations

¹ Howard Hughes Medical Institute, Cambridge, MA, USA.
² Broad Institute of MIT and Harvard, Cambridge, MA, USA.
³ McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
⁴ Department of Brain and Cognitive Science, Massachusetts Institute of Technology, Cambridge, MA, USA.
⁵ Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
⁶ Yang Tan Collective, Cambridge, MA, USA.
⁷ Howard Hughes Medical Institute, Cambridge, MA, USA. zhang@broadinstitute.org.
⁸ Broad Institute of MIT and Harvard, Cambridge, MA, USA. zhang@broadinstitute.org.
⁹ McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, MA, USA. zhang@broadinstitute.org.
¹⁰ Department of Brain and Cognitive Science, Massachusetts Institute of Technology, Cambridge, MA, USA. zhang@broadinstitute.org.
¹¹ Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. zhang@broadinstitute.org.
¹² Yang Tan Collective, Cambridge, MA, USA. zhang@broadinstitute.org.

^# Contributed equally.

PMID: 40335752
DOI: 10.1038/s41587-025-02655-3

Abstract

Naturally existing enzymes have been adapted for a variety of molecular technologies, with enhancements or modifications to the enzymes introduced to improve the desired function; however, it is difficult to engineer variants with enhanced activity while maintaining specificity. Here we engineer the compact Obligate Mobile Element Guided Activity (OMEGA) RNA-guided endonuclease IscB and its guiding RNA (ωRNA) by combining ortholog screening, structure-guided protein domain design and RNA engineering, and deep learning-based structure prediction to generate an improved variant, NovaIscB. We show that the compact NovaIscB achieves up to 40% indel activity (~100-fold improvement over wild-type OgeuIscB) on the human genome with improved specificity relative to existing IscBs. We further show that NovaIscB can be fused with a methyltransferase to create a programmable transcriptional repressor, OMEGAoff, that is compact enough to be packaged in a single adeno-associated virus vector for persistent in vivo gene repression. This study highlights the power of combining natural diversity with protein engineering to design enhanced enzymes for molecular biology applications.

PubMed Disclaimer

Conflict of interest statement

Competing interests: F.Z. is a scientific advisor and cofounder of Beam Therapeutics, Pairwise Plants, Arbor Biotechnologies, Aera Therapeutics and Moonwalk Biosciences. F.Z. is a scientific advisor for Octant. The other authors declare no competing interests.

References

1. Adashi, E. Y., Gruppuso, P. A. & Cohen, I. G. CRISPR therapy of sickle cell disease: the dawning of the gene editing era. Am. J. Med. 137, 390–392 (2024). - PubMed - DOI
1. Ran, F. A. et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186–191 (2015). - PubMed - PMC - DOI
1. Kim, E. et al. In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni. Nat. Commun. 8, 14500 (2017). - PubMed - PMC - DOI
1. Gasiunas, G. et al. A catalogue of biochemically diverse CRISPR–Cas9 orthologs. Nat. Commun. 11, 5512 (2020). - PubMed - PMC - DOI
1. Altae-Tran, H. et al. Diversity, evolution, and classification of the RNA-guided nucleases TnpB and Cas12. Proc. Natl Acad. Sci. USA 120, e2308224120 (2023). - PubMed - PMC - DOI

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Research Materials
- Addgene Non-profit plasmid repository

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Evolution-guided protein design of IscB for persistent epigenome editing in vivo

Affiliations

Evolution-guided protein design of IscB for persistent epigenome editing in vivo

Authors

Affiliations

Abstract

Conflict of interest statement

References

LinkOut - more resources

Full Text Sources

Research Materials